Drug Insights

Is Oliceridine approved by the FDA?

5 July 2024
3 min read

Yes, oliceridine (Olinvyk) is an FDA-approved intravenous opioid analgesic that offers a new option for managing severe acute pain. Approved on August 7, 2020, it is intended for patients who have not found relief with other treatments.

What is Oliceridine?

Oliceridine is an opioid analgesic used for the management of severe acute pain when other treatments are insufficient. It belongs to the drug class of opioids (narcotic analgesics) and is administered intravenously.

How Oliceridine Works

Oliceridine works by binding to the mu-opioid receptor in the brain, altering the perception of pain and emotional response to pain. Unlike traditional opioids, oliceridine is designed to provide effective pain relief with potentially fewer side effects, such as respiratory depression.

Administration and Dosage

Oliceridine is administered intravenously, usually through an infusion pump that allows for continuous dosing. The recommended dosing regimen is as follows:

Initial Dose:

  • 1.5 mg intravenously

Supplemental Dose:

  • 0.75 mg every hour as needed, starting 1 hour after the initial dose

Maximum Dose:

  • Single dose: 3 mg
  • Daily dose: 27 mg

For patient-controlled analgesia (PCA), the recommended demand dose is 0.35 mg with a 6-minute lockout period, with a maximum of 27 mg per day.

Potential Side Effects

Oliceridine can cause various side effects, ranging from common to severe:

Common Side Effects:

  • Nausea
  • Vomiting
  • Constipation
  • Headache
  • Dizziness
  • Itching
  • Low oxygen levels in the blood

Serious Side Effects:

  • Noisy or shallow breathing, sleep apnea
  • Slow heart rate, weak pulse
  • Light-headedness, potential fainting
  • Severe constipation
  • Low red blood cells (anemia)
  • Low cortisol levels
  • Low oxygen levels in the blood, leading to confusion, restlessness, or blue-colored lips/skin

Warnings and Precautions

Oliceridine carries the risk of addiction, overdose, and death, especially when misused or combined with alcohol and other sedatives. Other important precautions include:

  • Do not use if allergic to oliceridine, or if you have severe asthma, breathing problems, or a bowel obstruction.
  • Use during pregnancy can cause life-threatening withdrawal symptoms in the newborn.
  • Long-term use may affect fertility in both men and women.
  • Inform your doctor about any history of liver disease, respiratory disorders, low blood pressure, or any conditions affecting the brain, gallbladder, or pancreas.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

TauRx Applies for UK Marketing Authorisation for HMTM to Treat Alzheimer's Disease
Latest Hotspot
3 min read
TauRx Applies for UK Marketing Authorisation for HMTM to Treat Alzheimer's Disease
5 July 2024
TauRx Pharmaceuticals Ltd has revealed the filing of a Marketing Authorisation Application in the UK for hydromethylthionine mesylate (HMTM).
Read →
Is Risdiplam approved by the FDA?
Drug Insights
3 min read
Is Risdiplam approved by the FDA?
5 July 2024
risdiplam FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA.
Read →
FDA authorizes Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb)
Latest Hotspot
2 min read
FDA authorizes Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb)
5 July 2024
Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.
Read →
Is Tafasitamab approved by the FDA?
Drug Insights
3 min read
Is Tafasitamab approved by the FDA?
5 July 2024
tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.